

January 28, 2011

PRESS RELEASE

[Mitsubishi Tanabe Pharma Corporation](#)

## **Nycomed and Mitsubishi Tanabe Pharma to Terminate Collaborative Development of APTA-2217, Roflumilast for Treatment of Respiratory Diseases in Japanese Market**

**Osaka, Japan, January 28, 2011**---Mitsubishi Tanabe Pharma Corporation announced today that the Company and Nycomed (Head Office: Zurich, Switzerland) have mutually agreed to terminate the roflumilast collaboration for Japan as of today.

This termination is due to Mitsubishi Tanabe Pharma's strategic decision following a reprioritization of therapeutic fields. Under the terms of the agreement, Mitsubishi Tanabe Pharma will return all the rights to the product candidate to Nycomed, which will assume sole responsibility for the further development of roflumilast in Japan.

<Media enquiry>  
Corporate Communications Department  
Phone: +81 6-6205-5211